A new meta-analysis indicates a significant association between hormone therapy (HT) usage and increased risk of gastroesophageal reflux disease (GERD), especially with estrogen use or combined estrogen-progestogen therapy, based on five studies involving over one million participants. The study, which offers clarity on the long-debated connection between HT and GERD in postmenopausal women, prompts further research and encourages preventive lifestyle strategies for women considering HT to mitigate GERD symptoms.
New analysis reveals a significant link between previous or ongoing hormone usage and gastroesophageal reflux disease.
For years, there has been an ongoing debate about the potential connection between hormone therapy (HT) and a heightened risk of gastroesophageal reflux disease (GERD). A recent systematic review and meta-analysis aims to settle this debate, indicating a notable link between past or present HT use and GERD. The findings of this study were recently published in Menopause, the journal of The North American Menopause Society (NAMS).
GERD is one of the most common conditions in gastroenterology practice. Its global prevalence has been estimated at nearly 14%. Common symptoms include heartburn, dysphagia (difficulty swallowing), and chest pain. Anatomical abnormalities, such as hiatal hernia and obesity, have been identified as risk factors. A number of medications, including antidepressants, anti-inflammatory drugs, and HT have also been linked with GERD in multiple studies, although there have been conflicting results, especially with regard to HT.
Estrogen increases stomach acid production and is associated with higher levels of plasma nitric oxide, which is a key neurotransmitter for the relaxation of the lower esophageal sphincter (LES). Progesterone relaxes the esophageal muscles and the LES, allowing stomach acid to flow back into the esophagus, causing GERD symptoms. Previous research linked female sex hormones with GERD symptoms during pregnancy and with oral contraceptive use. However, the association between HT and GERD in postmenopausal women had remained unclear. A new systematic review and meta-analysis, however, provides clarity by confirming a significant association between ever or current HT use and GERD.
Researchers conducted an online search of published randomized, controlled trials and observational studies investigating the association between HT and GERD. Although a total of 84 studies were originally identified, most were eliminated because of irrelevancy or because they were duplicates or associated with conference abstracts. What remained for analysis were five full-length studies that covered more than one million participants. No participants with a prior GERD diagnosis were included.
All five studies reported a significant association between estrogen use and GERD, as well as between GERD and HT containing a combination of estrogen plus a progestogen. Women who received combined estrogen-progestogen therapies had a lower risk of GERD symptoms compared with HT containing estrogen alone or progestogen alone.
Additional research is suggested because of the small number of included studies. Hormone therapy has proven effective in treating many menopause symptoms. GERD risk factors should be considered when evaluating women with menopause symptoms.
“Although additional research is needed, this study highlights the potential for the development of GERD symptoms with HT use. A review of risk factors for GERD and implementation of lifestyle strategies for prevention, such as smoking cessation, maintaining a healthy weight, and not lying down after a heavy meal, may be helpful to avoid GERD symptoms in menopausal women considering HT use,” says Dr. Stephanie Faubion, NAMS medical director.